ESA Biosciences Names Jasmine Gruia-Gray, PhD, VP Of Life Sciences Marketing
ESA Biosciences, Inc., a Magellan Biosciences company and leader in analytical systems used in clinical and biomedical-research laboratories worldwide, has appointed Jasmine Gruia-Gray, PhD, vice president of life sciences marketing. Dr. Gruia-Gray joins ESA after a 10-year career at Amersham Biosciences, now GE Healthcare, where she was most recently director of marketing for the company's protein sciences/protein characterization business.
"We are delighted to welcome Jasmine to ESA," said Magellan President and Chief Executive Officer, Robert J. Rosenthal, PhD. "We are proud of ESA's many accomplishments as a leader in specialty detection. As the life-sciences marketplace constantly evolves, we too will push ourselves to remain a "go-to" partner for scientists with pressing analytical problems. Jasmine has the track record, experience, and confidence to be a leader and mentor at ESA. She will advance our culture of excellence and help drive a customer-centric approach across a range of critical internal and external processes, including market research and analysis, new product development, quality, order fulfillment, customer service, and applications support."
Dr. Gruia-Gray, commented, "The ESA brand has earned a stellar reputation over the years for its strong applications focus and I am honored to become a member of the ESA/Magellan team. It's an exciting time in life sciences. Today's dramatic leaps forward in our understanding of the chemical and biological mechanisms of health and disease are informing tomorrow's advances in diagnostics and therapeutics. We are committed to facilitating these discoveries by providing life-science customers with high-quality systems to help improve the outcomes of their research, and, equally important at the other end of the customer product continuum – to ensure exacting manufacturing standards for product quality. Over the next several months, I look forward to traveling to customer sites around the world in order to learn how we are meeting customers' expectations, and how we can better serve their needs in the future – an initial foray into what I expect will be a continuous and fruitful dialogue with customers."
Dr. Gruia-Gray started her career at Amersham, working with customers to troubleshoot their product and applications problems as a technical- support specialist in molecular biology. She advanced rapidly to become a product manager for specialty bioproducts. From 2000 to 2004, Dr. Gruia-Gray served as Amersham's director of marketing for proteomics. Under her leadership, the company's proteomics portfolio of hardware, software, and reagents products experienced double-digit growth. Before joining Amersham, she was science coordinator and research scientist at the New York University Medical Center/Salk School of Science, a collaboration between NYU and the New York City Department of Education that offers a science-enrichment curricula to New York middle school students. Dr. Gruia-Gray holds a PhD in molecular biology from the University of Toronto.
About ESA
ESA Biosciences, Inc. enables answers to pressing applications challenges by applying its expertise in specialty detection and electrochemistry, combined with components, kits, and reagents, for analytical laboratories, commercial diagnostics laboratories, and the clinical point-of-care setting. ESA is a wholly owned subsidiary of Magellan Biosciences, Inc. For more information, visit www.esainc.com.
About Magellan Biosciences
Magellan serves the worldwide clinical-diagnostics market with rapid point-of-care analyzers and automated systems for hospital-based labs and near-patient testing. Scientists use the company's discovery systems and sensors for cutting-edge research to develop a new understanding of health and illness – from disease pathology to biomarker identification. Magellan designs all its systems, sensors, and consumables to deliver better, more-reliable results. And better results help drive improved health outcomes: earlier, more-accurate diagnoses; breakthroughs that can lead to novel treatments, new cures – innovations to enhance life. A privately held company, Magellan serves customers through wholly owned subsidiaries: ESA Biosciences, Dynex Technologies, and TREK Diagnostic Systems. For more information, visit www.magellanbio.com.
SOURCE: ESA Biosciences, Inc.